STAAR Surgical Company (NASDAQ:STAA) filed its Form 10-Q for the quarterly period ended October 2, 2026, reporting third-quarter net sales of $83,411 thousand and net income of $5,575 thousand, with nine-month net income of $18,839 thousand compared to a net loss of $62,139 thousand in the prior-year period.

Key Highlights

  • Q3 net sales: $83,411 thousand for the three months ended October 2, 2026, compared to $94,732 thousand for the three months ended September 26, 2025, according to the filing.
  • Q3 net income: $5,575 thousand, or $0.11 per basic and diluted share, versus net income of $8,884 thousand, or $0.18 per basic and diluted share, in the prior-year quarter.
  • Nine-month net income: $18,839 thousand for the nine months ended October 2, 2026, compared to a net loss of $62,139 thousand for the nine months ended September 26, 2025.
  • Total assets: $485,156 thousand as of October 2, 2026, up from $451,678 thousand as of January 2, 2026.
  • Total stockholders' equity: $376,129 thousand at October 2, 2026, compared to $344,184 thousand at January 2, 2026.
  • Shares outstanding: 50,201,819 shares of common stock as of October 30, 2026, per the filing cover page.
  • Restructuring and merger costs: The company reported $6,743 thousand in merger transaction and related costs and $2,681 thousand in restructuring, impairment and related charges for the nine months ended October 2, 2026.

STAAR Surgical Third-Quarter and Nine-Month 2026 Financial Results

According to the filing, STAAR Surgical reported net sales of $83,411 thousand for the third quarter ended October 2, 2026, a decline from $94,732 thousand in the comparable prior-year quarter. Cost of sales rose to $24,276 thousand from $16,857 thousand, resulting in gross profit of $59,135 thousand versus $77,875 thousand a year earlier. Operating income for the quarter was $5,459 thousand, compared to $18,490 thousand in the prior-year period. The company recorded a provision for income taxes of $1,405 thousand in Q3 2026 versus $9,906 thousand in Q3 2025.

For the nine months ended October 2, 2026, the company reported net sales of $270,468 thousand, up from $181,641 thousand in the first nine months of fiscal 2025, the filing stated. The nine-month operating income was $23,539 thousand, compared to an operating loss of $68,875 thousand in the year-ago period. The prior-year nine-month results included $27,938 thousand in restructuring, impairment and related charges, and $5,926 thousand in merger transaction costs, versus $2,681 thousand and $6,743 thousand, respectively, in the current year-to-date period.

The condensed consolidated balance sheet reflected cash and cash equivalents of $133,610 thousand and investments available for sale of $72,804 thousand as of October 2, 2026, the company disclosed. Accounts receivable trade, net, was $86,528 thousand, up from $50,064 thousand at January 2, 2026. The accumulated deficit narrowed to $129,185 thousand from $148,024 thousand at the prior fiscal year-end. Stock-based compensation for the nine-month period was $17,221 thousand, and the company repurchased employee common stock for taxes withheld totaling $5,931 thousand.

What Was Disclosed

STAAR Surgical's 10-Q for the quarter ended October 2, 2026 presented condensed consolidated financial statements showing quarterly net sales of $83,411 thousand, quarterly net income of $5,575 thousand, and total assets of $485,156 thousand, alongside nine-month results reflecting a return to profitability versus the prior-year period.